[Toxicological Evaluation of Intravenous Formulation of Rifapentine.]

Area of Science:

• Pharmacology
• Drug Development
• Tuberculosis Research

Background:

• Rifapentine is a potent antituberculosis drug but faces clinical limitations due to poor solubility and side effects.
• Existing oral formulations of rifapentine can cause gastrointestinal and cardiac toxicity.

Purpose of the Study:

• To evaluate the toxicological profile of a novel intravenous rifapentine formulation.
• To compare the safety of the intravenous formulation with conventional oral rifapentine.

Main Methods:

• Development of an intravenous rifapentine formulation using human serum albumin.
• Acute and chronic toxicity testing of both oral and intravenous rifapentine formulations in experimental models.

Main Results:

• The intravenous rifapentine formulation exhibited low acute toxicity (LD₅₀ 340 mg/kg).
• Chronic toxicity studies revealed comparable adverse effects between oral and intravenous forms.
• The intravenous formulation demonstrated a significant reduction in gastrointestinal and cardiotoxic effects.

Conclusions:

• The intravenous rifapentine formulation is a potentially safer alternative to oral administration.
• This novel formulation may overcome key limitations of current rifapentine treatments.
• The reduced toxicity profile suggests improved clinical applicability for tuberculosis therapy.